A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine

Oncotarget
Jun Ho YiJun Ho Jang

Abstract

Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.

References

Jan 16, 2002·Current Opinion in Oncology·Mikkael A Sekeres, Richard M Stone
Sep 28, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Anoop Kumar EnjetiChristina Rudduck Sivaswaren
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda F CashenJohn F DiPersio
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Mar 3, 2012·Blood·Gunnar JuliussonUNKNOWN Swedish Acute Leukemia Registry Group
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 14, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellUNKNOWN National Comprehensive Cancer Network
Jul 6, 2014·International Journal of Hematology·Soo-Jeong KimUNKNOWN Korean Society of Hematology AML/MDS Working Party

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Software Mentioned

SPSS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.